Arecor Therapeutics (LON:AREC) Posts Quarterly Earnings Results

Arecor Therapeutics (LON:AREC) posted its earnings results on Thursday. The company reported GBX (8) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a net margin of 38.74% and a return on equity of 14.26%.

Arecor Therapeutics Stock Up 3.4%

AREC opened at GBX 75 on Thursday. Arecor Therapeutics has a fifty-two week low of GBX 56 and a fifty-two week high of GBX 95. The company has a debt-to-equity ratio of 1.52, a quick ratio of 6.24 and a current ratio of 4.35. The company has a fifty day moving average of GBX 71.57 and a two-hundred day moving average of GBX 67.96. The stock has a market capitalization of £28.32 million, a price-to-earnings ratio of 37.50 and a beta of -0.18.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.